News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
331,901 Results
Type
Article (19701)
Company Profile (140)
Press Release (312060)
Section
Business (106400)
Career Advice (865)
Deals (18791)
Drug Delivery (89)
Drug Development (50996)
Employer Resources (79)
FDA (7732)
Job Trends (7764)
News (187563)
Policy (17470)
Tag
Academia (734)
Alliances (28281)
Alzheimer's disease (560)
Approvals (7693)
Artificial intelligence (77)
Bankruptcy (170)
Best Places to Work (5515)
Biosimilars (68)
Biotechnology (61)
Cancer (485)
Career advice (703)
Cell therapy (70)
Clinical research (41866)
Collaboration (180)
Compensation (62)
COVID-19 (1073)
C-suite (52)
Data (503)
Diabetes (87)
Diagnostics (1776)
Drug pricing (90)
Earnings (38325)
Employer resources (73)
Events (47830)
Executive appointments (168)
FDA (7960)
Funding (136)
Gene therapy (82)
GLP-1 (476)
Government (1798)
Healthcare (5967)
Infectious disease (1120)
Inflammatory bowel disease (66)
Interviews (115)
IPO (7337)
Job creations (2440)
Job search strategy (645)
Layoffs (249)
Legal (4153)
Lung cancer (90)
Manufacturing (115)
Medical device (2079)
Medtech (2082)
Mergers & acquisitions (11473)
Metabolic disorders (304)
Neuroscience (708)
NextGen Class of 2024 (2365)
Non-profit (900)
Northern California (580)
Obesity (200)
Opinion (172)
Patents (67)
People (33081)
Pharmaceutical (75)
Phase I (13027)
Phase II (17745)
Phase III (14252)
Pipeline (161)
Podcasts (54)
Policy (66)
Postmarket research (1635)
Preclinical (4586)
Radiopharmaceuticals (158)
Rare diseases (126)
Real estate (3220)
Regulatory (12188)
Research institute (827)
Resumes & cover letters (138)
Southern California (542)
Startups (2034)
United States (5493)
Vaccines (207)
Weight loss (178)
Date
Today (119)
Last 7 days (445)
Last 30 days (1586)
Last 365 days (18023)
2024 (15654)
2023 (19859)
2022 (26564)
2021 (27334)
2020 (25384)
2019 (20320)
2018 (15746)
2017 (17517)
2016 (16453)
2015 (19124)
2014 (15031)
2013 (12749)
2012 (13733)
2011 (14026)
2010 (12914)
Location
Africa (407)
Arizona (50)
Asia (24626)
Australia (3246)
California (1310)
Canada (692)
China (128)
Colorado (55)
Connecticut (52)
Europe (52595)
Florida (178)
Illinois (130)
Indiana (109)
Kansas (55)
Maryland (216)
Massachusetts (1138)
Minnesota (78)
New Jersey (518)
New York (391)
North Carolina (347)
Northern California (580)
Ohio (61)
Pennsylvania (338)
South America (606)
Southern California (542)
Texas (165)
Washington State (128)
331,901 Results for "audiocure pharma gmbh".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
AudioCure Pharma Receives Hearing Technology Innovator Award for its Innovative Compound AC102 for the Treatment of Sudden Hearing Loss
AudioCure Pharma GmbH announced that it has been awarded for its innovative compound AC102 by the Hearing Technology Innovator Awards™, honoring technological innovation and breakthroughs in the hearing industry.
December 7, 2023
·
2 min read
FundaMental Pharma GmbH announces publication of a groundbreaking Proof-of-Concept Study in Cell Reports Medicine using a TwinF Interface Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis
FundaMental Pharma GmbH (‘FundaMental’ or ’the Company’), a neuroscience company developing first-in-class small molecule inhibitors for treatment of a range of neurodegenerative diseases, today announces the publication of a groundbreaking study by Neurobiologists in Heidelberg using FundaMental Pharma’s small molecule TwinF interface inhibitor, FP802.
February 7, 2024
·
3 min read
Drug Development
Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce FDA Clearance of the Investigational New Drug Application for Naronapride to Treat Gastroparesis and Subsequent Expansion of the Ongoing Phase 2b MOVE-IT Study to the United States
Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal (“GI”) disorders, and European partner, Dr. Falk Pharma GmbH (“Dr. Falk Pharma”), announce U.S Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for naronapride to treat patients with gastroparesis.
March 27, 2024
·
5 min read
Renexxion Ireland’s European Partner, Dr. Falk Pharma GmbH, has Elected PPI-non-responsive Symptomatic GERD as the Second Naronapride Indication to Develop and Commercialize in their Licensed Territories
Renexxion Ireland Limited announced that its European Partner, Dr. Falk Pharma GmbH, has elected to advance the development of naronapride for patients with proton-pump inhibitor non-responsive symptomatic gastroesophageal reflux disease as the second indication in their licensed territories.
February 7, 2024
·
5 min read
Press Releases
Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Expansion of the Phase 2b MOVE-IT Study of Naronapride in Gastroparesis and Dosing of the First United States Patient
August 13, 2024
·
6 min read
Business
FundaMental Pharma Appoints Industry Veteran Dr. Lorenz Mayr as Non-Executive Director
FundaMental Pharma GmbH announced the appointment of Dr. Lorenz Mayr to its Board of Directors.
March 20, 2024
·
3 min read
Drug Development
Sudden Hearing Loss: AudioCure’s Novel Compound AC102 Restores Hearing in Preclinical Models, Published in PNAS
A single application of the novel compound AC102 almost completely restores noise-induced hearing loss in preclinical models.
April 1, 2024
·
2 min read
Deals
Great Point Partners Acquires Lyocontract GmbH, Germany-Based Drug Product CDMO
Great Point Partners, a Greenwich-based investment firm focused exclusively on the health care industry, announced the acquisition of Lyocontract GmbH, a premium independent drug product contract development and manufacturing organization based in Ilsenburg, Germany.
June 13, 2024
·
3 min read
Business
FundaMental Pharma appoints Dr. Dirk Beher as Chief Executive Officer
FundaMental Pharma GmbH, a neuroscience company developing first-in-class small molecule inhibitors for the treatment of a range of neurodegenerative diseases, is pleased to announce the appointment of Dr. Dirk Beher as Chief Executive Officer and Executive Board member.
April 11, 2024
·
4 min read
Business
Oakwood Chemical Announces Strategic Partnership with EMP Biotech GmbH
Oakwood Chemical is thrilled to unveil its collaboration with EMP Biotech GmbH, a move set to streamline the oligo synthesis supply chain.
April 9, 2024
·
2 min read
1 of 33,191
Next
